Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Senseion LLC
Profile last edited on: 9/8/23      CAGE: 82PP9      UEI: NM86QKKPZ3V8

Business Identifier: Advancing firm's first-in-class drug candidate for metabolic disease
Year Founded
2017
First Award
2019
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

3715 Forest Gate Drive Northeast
Iowa City, IA 52240
   (917) 597-5535
   N/A
   N/A
Location: Single
Congr. District: 02
County: St. Louis

Public Profile

A preclinical-stage pharmaceutical company, Senseion Therapeutics is usefully understood as developing new medicines to treat metabolic diseases presenting global health challenges—specifically as associated with chloride ion-channel diseases. An arena of focus for the firm is the development of novel therapies to treat metabolic diseases and their complications including cardiovascular disease - the leading cause of death in patients with Type 2 diabetes.

Extent of SBIR involvement

User Avatar
Phase I Awards
1
Phase II Awards
1
Conversion Rate
100.00%
Phase I Dollars
$296,853
Phase II Dollars
$1,984,107
Total Awarded
$2,280,960

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2022 2 NIH $2,280,960
Project Title: Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes

Key People / Management

  Susheel Kumar Gunasekar

  Daniel J Lerner -- Co-Founder and Chief Executive Officer

  Rajan Sah -- Co-Founder and Chief Scientific Officer

Company News

There are no news available.